Evidence map›Paper›PMID 40860411›Full record

ArticleIndian journal of thoracic and cardiovascular surgery2025

From skin to lung: a rare case of PDZRN3/RAF1 fusion in recurrent dermatofibrosarcoma protuberans with lung metastasis.

Raja Chhabra, Sajjan Rajpurohit, Kshitij Bajpai, Jasbir Singh, Md Ali Osama

Abstract readCase Reports
In one paragraph

Article in Indian journal of thoracic and cardiovascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Raja ChhabraDepartment of Medical Oncology, BLK-MAX Super Speciality Hospital, Pusa Road, New Delhi, 110005 India.
Sajjan RajpurohitDepartment of Medical Oncology, BLK-MAX Super Speciality Hospital, Pusa Road, New Delhi, 110005 India.
Kshitij BajpaiDepartment of Medical Oncology, BLK-MAX Super Speciality Hospital, Pusa Road, New Delhi, 110005 India.
Jasbir SinghDepartment of Pathology, BLK-MAX Super Speciality Hospital, Pusa Road, New Delhi, India.
Md Ali OsamaDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.ORCID 0000-0002-0660-9939

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatofibrosarcoma protuberans (DFSP), a soft tissue neoplasm of intermediate grade not commonly encountered in oncology clinics, has been traditionally known for its locally aggressive nature and recurrence after surgical excision. This spindle cell neoplasm of fibro-histiocytic origin has one of its rare aggressive variants, pronounced by a high risk of local relapse and metastasis, recognized as fibrosarcomatous transformation of dermatofibrosarcoma protuberans (FS-DFSP). Here, we present a novel case of DFSP of the scalp which, after repeated local recurrences, transformed into an aggressive variant (FS-DFSP) with metastasis to the lungs. After comprehensive molecular profiling of the tumor, an infrequent PDZ Domain-Containing RING Finger 3-Rapidly Accelerated Fibrosarcoma 1 (PDZRN3/RAF1) gene fusion was identified, suggesting a plausible targetable chemotherapeutic option in the era of precision medicine. This case report also highlights the diagnostic conundrum faced by medical oncologists and radiologists, who, at first glance, thought of an invasive lung primary malignancy encasing the bronchus, but the histopathological findings turned out to be a flabbergasting surprise.

Indexed as

Dermatofibrosarcoma protuberansImmunohistochemistryLungMetastasisNext-generation sequencingPrecision medicine

Identifiers

PMID40860411
PMCPMC12373625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.